Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

Strong Balance Sheet Reflects Revenue Growth and New $125M Five-Year FacilityNEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$35.1 million on Ryoncil® (remestemcel-L-rknd) sales for the quarter ended December 31, 2025.1 This represents a 60% increase on the prior quarter ended September 30, 2025. Ryoncil® is the first mesenchymal stromal cell (MSC) product approv ...